A Randomized, Single-blind, Threefold Crossover, Single-center Study to Assess the Safety and the Effects of 1 mg and 5 mg BAY1193397 in Comparison to Placebo on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure After Single Dose in Type II Diabetic Patients
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs BAY 1193397 (Primary)
- Indications Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors Bayer
- 01 Nov 2019 Status changed from active, no longer recruiting to completed.
- 25 Jul 2019 Planned number of patients changed from 18 to 22.
- 27 Feb 2019 Planned End Date changed from 7 Jun 2019 to 29 Oct 2019.